Fabric Genomics Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Fabric Genomics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013943
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Fabric Genomics Inc (Fabric), formerly Omicia Inc is a healthcare solutions provider that offers genome analysis services. The company provides solutions for researchers and clinicians to analyze genomes and disease-causing variants and genes. Its products include opal software and standalone software. Fabric’s opal software offers opal clinical, opal research, opal in silico panels, and opal clinical trials. Omicia’s opal clinical software interprets and reports platform for clinical testing on targeted gene panels, exomes and whole genomes. The company’s VAAST is a disease gene finder and variant scoring algorithm used in academic and clinical institutions. It serves commercial clinical laboratories, country sequencing programs, hospital core labs, and research institutions. Omicia is headquartered in Oakland, California, the US.

Fabric Genomics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Fabric Genomics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Fabric Genomics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Fabric Genomics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Fabric Genomics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Fabric Genomics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Fabric Genomics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Fabric Genomics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Omicia Raises US$7 Million In Series A Financing Round 11
Partnerships 12
Edico Genome Enters Into Partnership With Fabric Genomics 12
Fabric Genomics Enters into Agreement with ITTM 13
Real Time Genomics Enters Into Technology Integration Agreement With Omicia 14
Spiral Genetics Enters Into Agreement With Omicia To Analyze Genomes And Prioritize Disease-Causing Variants 15
Licensing Agreements 16
Omicia Enters Into Licensing Agreement With University of Utah Health Sciences 16
Fabric Genomics Inc – Key Competitors 17
Fabric Genomics Inc – Key Employees 18
Fabric Genomics Inc – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Corporate Communications 20
Mar 03, 2016: Omicia Announces Appointment of Matt Tindall as Chief Executive Officer 20
Product News 21
Mar 09, 2016: Omicia Implements ACMG Variant Scoring and Classification Guidelines to Drive Clinical NGS Report Consistency and Throughput 21
Other Significant Developments 22
Mar 21, 2017: Omicia Rebrands as Fabric Genomics; Launches New End-to-End Computational Genomics Platform 22
Oct 17, 2016: Omicia Delivers Clinical Reports for 100,000 Genomes Project Main Program 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Fabric Genomics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Fabric Genomics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Fabric Genomics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Fabric Genomics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Fabric Genomics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Fabric Genomics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Fabric Genomics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Omicia Raises US$7 Million In Series A Financing Round 11
Edico Genome Enters Into Partnership With Fabric Genomics 12
Fabric Genomics Enters into Agreement with ITTM 13
Real Time Genomics Enters Into Technology Integration Agreement With Omicia 14
Spiral Genetics Enters Into Agreement With Omicia To Analyze Genomes And Prioritize Disease-Causing Variants 15
Omicia Enters Into Licensing Agreement With University of Utah Health Sciences 16
Fabric Genomics Inc, Key Competitors 17
Fabric Genomics Inc, Key Employees 18
Fabric Genomics Inc, Subsidiaries 19

★海外企業調査レポート[Fabric Genomics Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fieldwood Energy LLC:石油・ガス:M&Aディール及び事業提携情報
    Summary Fieldwood Energy LLC (Fieldwood Energy) is an energy and power-focused investment firm. The company operates 500 offshore blocks on the Gulf of Mexico Shelf which focuses on acquiring and developing conventional assets. Fieldwood Energy is portfolio company of Riverstone Holdings LLC. The Co …
  • Nippon Yusen Kabushiki Kaisha (9101)-石油・ガス分野:企業M&A・提携分析
    Summary Nippon Yusen Kabushiki Kaisha (NYK) is a logistics company transporting crude oil and allied products. The company provides ocean, land, and air transport services for the transportation of petroleum products, liquid products and dry bulk products. Its portfolio includes line trade, air carg …
  • Can-Fite BioPharma Ltd (CANF):企業の財務・戦略的SWOT分析
    Summary Can-Fite BioPharma Ltd (Can-Fite) is a clinical stage drug development Company that strives to develop small molecule drugs for the treatment of cancer and inflammatory diseases. The company’s pipeline products which are in phase II and III clinical development stage includes CF101, for rheu …
  • Fraser & Neave Holdings Bhd:戦略・SWOT・企業財務分析
    Fraser & Neave Holdings Bhd - Strategy, SWOT and Corporate Finance Report Summary Fraser & Neave Holdings Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • German Cancer Research Center-製薬・医療分野:企業M&A・提携分析
    Summary German Cancer Research Center (DKFZ) is a biomedical research institute that develops therapies for the treatment of cancer patients. The institute’s research programs include translational cancer research, cell biology and tumor biology, imaging and radiooncology, cancer risk factors and pr …
  • Intrexon Corp (XON):製薬・医療:M&Aディール及び事業提携情報
    Summary Intrexon Corp (Intrexon), formerly Genomatix Corp is a synthetic biology service provider. The company operates through its divisions and units such as cell engineering, data sciences and computational biology, information technology (IT), actobiotics, molecular engineering, agricultural bio …
  • Fiat Chrysler Automobiles NV:企業の戦略・SWOT・財務情報
    Fiat Chrysler Automobiles NV - Strategy, SWOT and Corporate Finance Report Summary Fiat Chrysler Automobiles NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • HRG Group, Inc. (HRG)-石油・ガス分野:企業M&A・提携分析
    Summary HRG Group, Inc. (HRG), formerly, Harbinger Group Inc., is a diversified investment holding company, with interests in various businesses such as branded consumer products, which include consumer batteries, residential locksets, faucets, shaving and grooming products, personal care products, …
  • Globavir Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary Globavir Biosciences Inc (Globavir) is a biotechnology company that develop combination of drug therapies and diagnostic tests in the therapeutic areas of infection and immune-oncology. The company develops Globavir’s Drug Discovery Platform (GDDP), which generates small molecule candidates …
  • Biofortuna Ltd:企業の製品パイプライン分析2018
    Summary Biofortuna Ltd (Biofortuna) is a provider of contract services and molecular diagnostic products. The company distributes CE-marked and freeze-dried PCR diagnostic kits. It has freeze dried molecular diagnostic products targeted at the transplantation, disease identification and pharmacogene …
  • Saladax Biomedical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Saladax Biomedical Inc (Saladax) is a medical equipment company that develops diagnostic tests. The company provides products such as My5-FU, MyPaclitaxel, MyImatinib and MyDocetaxel, among others. Its My5-FU measures and helps physicians to optimize a patient’s exposure to 5-fluorouracil, M …
  • Red Rock Resorts, Inc. (RRR):企業の財務・戦略的SWOT分析
    Red Rock Resorts, Inc. (RRR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • General Re Corporation:企業の戦略的SWOT分析
    General Re Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Janssen Pharmaceuticals, Inc.:企業のM&A・事業提携・投資動向
    Janssen Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Janssen Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Sarawak Energy Berhad:企業の戦略的SWOT分析
    Sarawak Energy Berhad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Pioneer Natural Resources Co Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Pioneer Natural Resources Co Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Pioneer Natural Resources Co (Pioneer) is an independent oil and natural gas exploration and production company. Its principally operates in Eagle Ford Shale, Permian Basin, Raton Basin, …
  • Natural Alternatives International Inc (NAII):企業の財務・戦略的SWOT分析
    Summary Natural Alternatives International Inc (NAI) is a formulator and manufacturer of customized nutritional supplements. It manufactures and distributes the only patented beta-alanine supplement CarnoSyn. It offers services such as science-based product formulation, raw material acquisition and …
  • Environmental Tectonics Corp:企業の戦略・SWOT・財務分析
    Environmental Tectonics Corp - Strategy, SWOT and Corporate Finance Report Summary Environmental Tectonics Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • PAR Technology Corp (PAR):企業の財務・戦略的SWOT分析
    Summary PAR Technology Corp (PAR) is a technology company that offers systems and solutions for the hospitality industry. The company offers services such as project management, education services, deployment services, on-site field services, depot repair, and managed services. It also implements fo …
  • Xodus Group Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Xodus Group Ltd (Xodus) is a provider of engineering and advisory services. The company offers services such as exploration and appraisal, development, projects, asset support, decommissioning and advisory services. Its exploration services comprise regional studies, basin modelling, acreage …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆